Nanobiotix (NASDAQ:NBTX) Hits New 12-Month High – Time to Buy?

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX)’s share price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $18.49 and last traded at $18.02, with a volume of 167265 shares changing hands. The stock had previously closed at $16.24.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Leerink Partners set a $14.00 target price on shares of Nanobiotix in a research report on Thursday, September 18th. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a report on Friday, September 19th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Nanobiotix Stock Down 0.8%

The business’s 50 day moving average price is $9.73 and its two-hundred day moving average price is $6.02.

Hedge Funds Weigh In On Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Jane Street Group LLC acquired a new stake in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,283 shares of the company’s stock, valued at approximately $73,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.